TTR and polyneuropathy: An alternative treatment approach involves TTR stabilizers, including tafamidis, to prevent dissociation of tetrameric TTR into its constituent monomers.9 While approved in the United States for the treatment of ATTR cardiomyopathy,10 tafamidis has variable efficacy in patients with later-stage polyneuropathy and may be mutation dependent for this symptom in hereditable ATTR.11